Physician profile
Nabil A Barsoum
NPI 1396717278
$2,175.70
in general payments reported to CMS, 2019-2025
15 companies · $22.56 in 2025
The $22.56 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $244 · 2021: $422 · 2022: $527 · 2023: $78.39 · 2024: $112 · 2025: $22.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $474.87 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $454.55 | 2019-2022 | |
| Indivior INC. | $310.40 | 2019-2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $244.78 | 2019-2024 | Xtampza |
| Mylan Specialty L.P. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $122.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $119.01 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $113.75 | 2019 | |
| Orexo US, INC. | $98.36 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $27.03 | 2020-2021 | |
| Pacira Therapeutics, INC. | $23.09 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $18.10 | 2022 | |
| Pfizer INC. | $16.15 | 2021 | |
| Depuy Synthes Sales INC. | $15.30 | 2021 | |
| Kaleo, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Barsoum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.